French company Carmat announced that its prosthetic heart was bought and transplanted into an Italian patient in a Naples hospital.
A French prosthetics company announced on July 19, that it sold its first artificial heart. Carmat, the French company, announced that its artificial heart was bought and transplanted into an Italian patient.
Carmat stated that the procedure "was performed by the team headed by heart surgeon Dr Ciro Maiello at the Azienda Ospedaliera dei Colli hospital in Naples, one of the centres with the greatest experience in the field of artificial hearts in Italy."
The artificial heart, marketed as the Aeson prosthetic heart, got the certification to be sold in the European Union in December 2020. The certification for the French company, which was founded in 2008, came based on the PIVOTAL research that had started in 2016 and which is still ongoing.
Carmat said the sale of the Aeson heart signified "a major milestone that opens up a new chapter in the company's development." The company also added that it was looking to help more customers in France and Germany by the end of the year.
The artificial heart helps patients who need immediate transplants but have to wait for the relevantorgans. According to a study in 2019, 73 percent of the patients survived the transplant for six months or until a successful permanent transplant within the same period.
While the treatment may prove to be lifesaving, the costs may be prohibitive. The surgical operation cost over 150,000 euros, which was paid for by the regional health system. The national system in Italy will not cover the procedure until it has been proven to be safe over several years.
(Edited by : Shoma Bhattacharjee)
First Published: IST